Targeted in situ therapeutic delivery of secreted factors from stem cells for treatment of damaged tissue
Inventors
Myung, David • Fernandes-Cunha, Gabriella • LEE, Hyun Jong • Djalilian, Ali
Assignees
United States Department of Veterans Affairs • Leland Stanford Junior University • University of Illinois System
Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Publication Number
US-12558458-B2
Publication Date
2026-02-24
Expiration Date
Abstract
Compositions and methods for repairing or regenerating damaged tissue are disclosed. In particular, the invention relates to methods of delivering secreted factors from stem cells to tissues in order to immobilize and concentrate such secreted factors at or under the surface of damaged tissue to promote tissue regeneration.
Core Innovation
The invention relates to accelerating wound healing and reducing neovascularization and scar formation in damaged tissue in a subject by applying a bone marrow-derived mesenchymal stem cell (MSC) secretome to the damaged tissue at or under the surface. The method includes collecting the bone marrow-derived MSC secretome from a mesenchymal stem cell and using the secretome to drive therapeutic effects in the damaged tissue.
A key part of the method is forming a mixture by combining the bone marrow-derived MSC secretome with a solution comprising at least one biocompatible polymer or biopolymer. In particular, the at least one biocompatible polymer or biopolymer comprises a mixture of hyaluronic acid and chondroitin sulfate, and the mixture is applied to the damaged tissue such that the MSC secretome accelerates healing at or under the surface.
The damaged tissue is ocular tissue, and more specifically the ocular tissue is corneal or stromal tissue. The bone marrow-derived MSC secretome reduces neovascularization and scar formation in the damaged tissue, with the ocular context focusing on corneal and/or stromal injury and the associated healing, vascularization, and scarring outcomes.
Claims Coverage
The provided material identifies one independent claim directed to a method in damaged tissue. The independent claim includes three main inventive elements: collecting a bone marrow-derived MSC secretome, mixing it with a biocompatible polymer/biopolymer solution comprising hyaluronic acid and chondroitin sulfate, and applying the resulting mixture to ocular corneal or stromal tissue to accelerate healing while reducing neovascularization and scar formation.
Secretome-based wound healing in damaged ocular tissue
A method comprising collecting a bone marrow-derived mesenchymal stem cell (MSC) secretome from a mesenchymal stem cell and applying the bone marrow-derived MSC secretome to damaged tissue at or under the surface, wherein the damaged tissue is ocular tissue, and wherein the ocular tissue is corneal or stromal tissue.
Ha/cs mixture with bone marrow-derived MSC secretome
Mixing the bone marrow-derived MSC secretome with a solution comprising at least one biocompatible polymer or biopolymer to form a mixture, wherein the at least one biocompatible polymer or biopolymer comprises a mixture of hyaluronic acid and chondroitin sulfate.
Accelerating healing while reducing neovascularization and scar formation
Applying the mixture to the damaged tissue wherein the bone marrow-derived MSC secretome accelerates healing at or under the surface of the damaged tissue and wherein the bone marrow-derived MSC secretome reduces neovascularization and scar formation in the damaged tissue.
Across the independent claim, the inventive concept is driven by applying a bone marrow-derived MSC secretome to ocular corneal or stromal damaged tissue at or under the surface, with the secretome formed into a mixture using a biocompatible polymer/biopolymer solution comprising hyaluronic acid and chondroitin sulfate, to accelerate healing while reducing neovascularization and scar formation.
Stated Advantages
Accelerates healing at or under the surface of the damaged tissue.
Reduces neovascularization in the damaged tissue.
Reduces scar formation in the damaged tissue.
Documented Applications
Treating ocular tissue with damaged corneal or stromal tissue using the described method to accelerate healing while reducing neovascularization and scar formation.
Treating ocular tissue damage caused by one or more specified ocular conditions or injuries, including chemical burns, dry eye disorders, inflammatory/autoimmune eye diseases, trauma, corneal surface disorders, and other ocular injuries or degenerations listed in the partial claim material.
Interested in licensing this patent?